270 related articles for article (PubMed ID: 33189702)
1. Association Between Preadmission Acid Suppressive Medication Exposure and Severity of Illness in Patients Hospitalized With COVID-19.
Elmunzer BJ; Wolf BJ; Scheiman JM; Tierney WM; Taylor JR;
Gastroenterology; 2021 Mar; 160(4):1417-1422.e14. PubMed ID: 33189702
[No Abstract] [Full Text] [Related]
2. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
[TBL] [Abstract][Full Text] [Related]
3. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study.
Song TJ; Kim J
PLoS One; 2019; 14(5):e0216750. PubMed ID: 31067267
[TBL] [Abstract][Full Text] [Related]
4. Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia.
Herzig SJ; Doughty C; Lahoti S; Marchina S; Sanan N; Feng W; Kumar S
Ann Neurol; 2014 Nov; 76(5):712-8. PubMed ID: 25164323
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis.
Pranata R; Huang I; Lawrensia S; Henrina J; Lim MA; Lukito AA; Kuswardhani RAT; Wibawa IDN
Pharmacol Rep; 2021 Dec; 73(6):1642-1649. PubMed ID: 33840053
[TBL] [Abstract][Full Text] [Related]
6. Effect of Acid Suppressants on the Risk of COVID-19: A Propensity Score-Matched Study Using UK Biobank.
Fan X; Liu Z; Miyata T; Dasarathy S; Rotroff DM; Wu X; Poulsen KL; Nagy LE
Gastroenterology; 2021 Jan; 160(1):455-458.e5. PubMed ID: 32980342
[No Abstract] [Full Text] [Related]
7. Histamine H2-Blocker and Proton Pump Inhibitor Use and the Risk of Pneumonia in Acute Stroke: A Retrospective Analysis on Susceptible Patients.
Arai N; Nakamizo T; Ihara H; Koide T; Nakamura A; Tabuse M; Miyazaki H
PLoS One; 2017; 12(1):e0169300. PubMed ID: 28085910
[TBL] [Abstract][Full Text] [Related]
8. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.
Deshpande A; Pasupuleti V; Thota P; Pant C; Mapara S; Hassan S; Rolston DD; Sferra TJ; Hernandez AV
J Gastroenterol Hepatol; 2013 Feb; 28(2):235-42. PubMed ID: 23190338
[TBL] [Abstract][Full Text] [Related]
9. Acid-suppressive medication use and the risk for nosocomial gastrointestinal tract bleeding.
Herzig SJ; Vaughn BP; Howell MD; Ngo LH; Marcantonio ER
Arch Intern Med; 2011 Jun; 171(11):991-7. PubMed ID: 21321285
[TBL] [Abstract][Full Text] [Related]
10. Gastric Acid Suppressant Prophylaxis in Pediatric Intensive Care: Current Practice as Reflected in a Large Administrative Database.
Costarino AT; Dai D; Feng R; Feudtner C; Guevara JP
Pediatr Crit Care Med; 2015 Sep; 16(7):605-12. PubMed ID: 25901549
[TBL] [Abstract][Full Text] [Related]
11. Acid suppressive therapy in noncritically ill patients.
Barletta JF; El-Ibiary SY
Arch Intern Med; 2011 Nov; 171(20):1861; author reply 1861-2. PubMed ID: 22083578
[No Abstract] [Full Text] [Related]
12. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists.
Houben E; Johansson S; Nagy P; Penning-van Beest FJA; Kuipers EJ; Herings RMC
Curr Med Res Opin; 2018 Apr; 34(4):577-583. PubMed ID: 29149805
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center.
McCaleb RV; Gandhi AS; Clark SM; Clemmons AB
Ann Pharmacother; 2016 Jul; 50(7):541-7. PubMed ID: 27091869
[TBL] [Abstract][Full Text] [Related]
14. Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19.
Yozgat A; Kasapoğlu B; Can G; Tanoğlu A; Sakin YS; Yalçın KS; Gürler M; Kaplan M; Kaban MG; Kırsoy M; Kara U; Kekilli M
Turk J Med Sci; 2021 Aug; 51(3):1675-1681. PubMed ID: 34110723
[TBL] [Abstract][Full Text] [Related]
15. Potential Biases in Studies of Acid-Suppressing Drugs and COVID-19 Infection.
Etminan M; Nazemipour M; Candidate MS; Mansournia MA
Gastroenterology; 2021 Apr; 160(5):1443-1446. PubMed ID: 33340538
[No Abstract] [Full Text] [Related]
16. Histamine 2 Receptor Antagonists and Proton Pump Inhibitors.
Brinkworth MD; Aouthmany M; Sheehan M
Dermatitis; 2016; 27(3):100-9. PubMed ID: 27172303
[TBL] [Abstract][Full Text] [Related]
17. Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke.
Momosaki R; Yasunaga H; Matsui H; Fushimi K; Abo M
J Stroke Cerebrovasc Dis; 2016 May; 25(5):1035-1040. PubMed ID: 26853142
[TBL] [Abstract][Full Text] [Related]
18. Risk of Clostridium difficile infection with acid-suppressive therapy; pitfalls in accurate estimation.
Chandra S; Agarwal D; Surana A
Am J Gastroenterol; 2013 Feb; 108(2):277-8. PubMed ID: 23381074
[No Abstract] [Full Text] [Related]
19. Pneumonia prevention in intubated patients given sucralfate versus proton-pump inhibitors and/or histamine II receptor blockers.
Grindlinger GA; Cairo SB; Duperre CB
J Surg Res; 2016 Dec; 206(2):398-404. PubMed ID: 27884335
[TBL] [Abstract][Full Text] [Related]
20. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.
Mattos ÂZ; Marchese GM; Fonseca BB; Kupski C; Machado MB
Arq Gastroenterol; 2017 Dec; 54(4):271-280. PubMed ID: 28954042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
